Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome

Integrins αvβ3 and αvβ5 regulate angiogenesis and invasiveness in cancer, potentially by modulating activation of the transforming growth factor (TGF)-β pathway. The randomized phase III CENTRIC and phase II CORE trials explored the integrin inhibitor cilengitide in patients with newly diagnosed gli...

Full description

Bibliographic Details
Main Authors:	Weller, Michael, Nabors, Louis Burt, Gorlia, Thierry, Leske, Henning, Rushing, Elisabeth, Bady, Pierre, Hicking, Christine, Perry, James, Hong, Yong-Kil, Roth, Patrick, Wick, Wolfgang, Goodman, Simon L., Hegi, Monika E., Picard, Martin, Moch, Holger, Straub, Josef, Stupp, Roger
Format:	Online
Language:	English
Published:	Impact Journals LLC 2016
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4924768/

id	pubmed-4924768
recordtype	oai_dc
spelling	pubmed-49247682016-07-13 Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome Weller, Michael Nabors, Louis Burt Gorlia, Thierry Leske, Henning Rushing, Elisabeth Bady, Pierre Hicking, Christine Perry, James Hong, Yong-Kil Roth, Patrick Wick, Wolfgang Goodman, Simon L. Hegi, Monika E. Picard, Martin Moch, Holger Straub, Josef Stupp, Roger Research Paper Integrins αvβ3 and αvβ5 regulate angiogenesis and invasiveness in cancer, potentially by modulating activation of the transforming growth factor (TGF)-β pathway. The randomized phase III CENTRIC and phase II CORE trials explored the integrin inhibitor cilengitide in patients with newly diagnosed glioblastoma with versus without O6-methylguanine DNA methyltransferase (MGMT) promoter methylation. These trials failed to meet their primary endpoints. Impact Journals LLC 2016-02-22 /pmc/articles/PMC4924768/ /pubmed/26918452 http://dx.doi.org/10.18632/oncotarget.7588 Text en Copyright: © 2016 Weller et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
repository_type	Open Access Journal
institution_category	Foreign Institution
institution	US National Center for Biotechnology Information
building	NCBI PubMed
collection	Online Access
language	English
format	Online
author	Weller, Michael Nabors, Louis Burt Gorlia, Thierry Leske, Henning Rushing, Elisabeth Bady, Pierre Hicking, Christine Perry, James Hong, Yong-Kil Roth, Patrick Wick, Wolfgang Goodman, Simon L. Hegi, Monika E. Picard, Martin Moch, Holger Straub, Josef Stupp, Roger
spellingShingle	Weller, Michael Nabors, Louis Burt Gorlia, Thierry Leske, Henning Rushing, Elisabeth Bady, Pierre Hicking, Christine Perry, James Hong, Yong-Kil Roth, Patrick Wick, Wolfgang Goodman, Simon L. Hegi, Monika E. Picard, Martin Moch, Holger Straub, Josef Stupp, Roger Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome
author_facet	Weller, Michael Nabors, Louis Burt Gorlia, Thierry Leske, Henning Rushing, Elisabeth Bady, Pierre Hicking, Christine Perry, James Hong, Yong-Kil Roth, Patrick Wick, Wolfgang Goodman, Simon L. Hegi, Monika E. Picard, Martin Moch, Holger Straub, Josef Stupp, Roger
author_sort	Weller, Michael
title	Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome
title_short	Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome
title_full	Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome
title_fullStr	Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome
title_full_unstemmed	Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome
title_sort	cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome
description	Integrins αvβ3 and αvβ5 regulate angiogenesis and invasiveness in cancer, potentially by modulating activation of the transforming growth factor (TGF)-β pathway. The randomized phase III CENTRIC and phase II CORE trials explored the integrin inhibitor cilengitide in patients with newly diagnosed glioblastoma with versus without O6-methylguanine DNA methyltransferase (MGMT) promoter methylation. These trials failed to meet their primary endpoints.
publisher	Impact Journals LLC
publishDate	2016
url	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4924768/
_version_	1613600932714512384

Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome

Similar Items